These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

756 related articles for article (PubMed ID: 29101402)

  • 21. Efficacy of the novel antidepressant agomelatine on the circadian rest-activity cycle and depressive and anxiety symptoms in patients with major depressive disorder: a randomized, double-blind comparison with sertraline.
    Kasper S; Hajak G; Wulff K; Hoogendijk WJ; Montejo AL; Smeraldi E; Rybakowski JK; Quera-Salva MA; Wirz-Justice AM; Picarel-Blanchot F; Baylé FJ
    J Clin Psychiatry; 2010 Feb; 71(2):109-20. PubMed ID: 20193645
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacological interventions for the treatment of depression in chronic obstructive pulmonary disease.
    Pollok J; van Agteren JE; Carson-Chahhoud KV
    Cochrane Database Syst Rev; 2018 Dec; 12(12):CD012346. PubMed ID: 30566235
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Escitalopram versus sertraline in the treatment of major depressive disorder: a randomized clinical trial.
    Ventura D; Armstrong EP; Skrepnek GH; Haim Erder M
    Curr Med Res Opin; 2007 Feb; 23(2):245-50. PubMed ID: 17288677
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Venlafaxine extended-release for depression following spinal cord injury: a randomized clinical trial.
    Fann JR; Bombardier CH; Richards JS; Wilson CS; Heinemann AW; Warren AM; Brooks L; McCullumsmith CB; Temkin NR; Warms C; Tate DG;
    JAMA Psychiatry; 2015 Mar; 72(3):247-58. PubMed ID: 25607727
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Milnacipran and venlafaxine at flexible doses (up to 200 mg/d) in the outpatient treatment of adults with moderate-to-severe major depressive disorder: a 24-week randomised, double blind exploratory study].
    Olié JP; Gourion D; Montagne A; Rostin M; Poirier MF
    Encephale; 2009 Dec; 35(6):595-604. PubMed ID: 20004291
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Lisdexamfetamine dimesylate augmentation for adults with major depressive disorder and inadequate response to antidepressant monotherapy: Results from 2 phase 3, multicenter, randomized, double-blind, placebo-controlled studies.
    Richards C; McIntyre RS; Weisler R; Sambunaris A; Brawman-Mintzer O; Gao J; Geibel B; Dauphin M; Madhoo M
    J Affect Disord; 2016 Dec; 206():151-160. PubMed ID: 27474961
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy of Sertraline in Patients With Major Depressive Disorder Naive to Selective Serotonin Reuptake Inhibitors: A 10-Week Randomized, Multicenter, Placebo-Controlled, Double-Blind, Academic Clinical Trial.
    Valle-Cabrera R; Mendoza-Rodríguez Y; Robaina-García M; Ballesteros J; Cordero-Jiménez JR; Espinosa-Rodríguez NB; Sotolongo-Garcia Y; Lauria-Horner B;
    J Clin Psychopharmacol; 2018 Oct; 38(5):454-459. PubMed ID: 30106883
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Omega-3 augmentation of sertraline in treatment of depression in patients with coronary heart disease: a randomized controlled trial.
    Carney RM; Freedland KE; Rubin EH; Rich MW; Steinmeyer BC; Harris WS
    JAMA; 2009 Oct; 302(15):1651-7. PubMed ID: 19843899
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A placebo-controlled comparison of the antidepressant efficacy and effects on sexual functioning of sustained-release bupropion and sertraline.
    Croft H; Settle E; Houser T; Batey SR; Donahue RM; Ascher JA
    Clin Ther; 1999 Apr; 21(4):643-58. PubMed ID: 10363731
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparative Efficacy of Therapies for Treatment of Depression for Patients Undergoing Maintenance Hemodialysis: A Randomized Clinical Trial.
    Mehrotra R; Cukor D; Unruh M; Rue T; Heagerty P; Cohen SD; Dember LM; Diaz-Linhart Y; Dubovsky A; Greene T; Grote N; Kutner N; Trivedi MH; Quinn DK; Ver Halen N; Weisbord SD; Young BA; Kimmel PL; Hedayati SS
    Ann Intern Med; 2019 Mar; 170(6):369-379. PubMed ID: 30802897
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Early and sustained improvement with vilazodone in adult patients with major depressive disorder: post hoc analyses of two phase III trials.
    Jain R; Chen D; Edwards J; Mathews M
    Curr Med Res Opin; 2014 Feb; 30(2):263-70. PubMed ID: 24127687
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Use of antidepressant drugs in schizophrenic patients with depression].
    Micallef J; Fakra E; Blin O
    Encephale; 2006; 32(2 Pt 1):263-9. PubMed ID: 16910628
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effectiveness of low doses of paroxetine controlled release in the treatment of major depressive disorder.
    Trivedi MH; Pigotti TA; Perera P; Dillingham KE; Carfagno ML; Pitts CD
    J Clin Psychiatry; 2004 Oct; 65(10):1356-64. PubMed ID: 15491239
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A study of the effects of LY2216684, a selective norepinephrine reuptake inhibitor, in the treatment of major depression.
    Dubé S; Dellva MA; Jones M; Kielbasa W; Padich R; Saha A; Rao P
    J Psychiatr Res; 2010 Apr; 44(6):356-63. PubMed ID: 19909980
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Onset of major depression associated with acute coronary syndromes: relationship of onset, major depressive disorder history, and episode severity to sertraline benefit.
    Glassman AH; Bigger JT; Gaffney M; Shapiro PA; Swenson JR
    Arch Gen Psychiatry; 2006 Mar; 63(3):283-8. PubMed ID: 16520433
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder: A Randomized Clinical Trial.
    Davis AK; Barrett FS; May DG; Cosimano MP; Sepeda ND; Johnson MW; Finan PH; Griffiths RR
    JAMA Psychiatry; 2021 May; 78(5):481-489. PubMed ID: 33146667
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Psychiatric characteristics associated with long-term mortality among 361 patients having an acute coronary syndrome and major depression: seven-year follow-up of SADHART participants.
    Glassman AH; Bigger JT; Gaffney M
    Arch Gen Psychiatry; 2009 Sep; 66(9):1022-9. PubMed ID: 19736359
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of Hypericum perforatum (St John's wort) in major depressive disorder: a randomized controlled trial.
    ; Davidson JR; Gadde KM; Fairbank JA; Krishnan KRR; Califf RM; Binanay C; Parker CB; Pugh N; Hartwell TD; Vitiello B; Ritz L; Severe J; Cole JO; de Battista C; Doraiswamy PM; Feighner JP; Keck P; Kelsey J; Lin KM; Londborg PD; Nemeroff CB; Schatzberg AF; Sheehan DV; Srivastava RK; Taylor L; Trivedi MH; Weisler RH
    JAMA; 2002 Apr; 287(14):1807-14. PubMed ID: 11939866
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Edivoxetine compared to placebo as adjunctive therapy to selective serotonin reuptake inhibitors in the prevention of symptom re-emergence in major depressive disorder.
    Oakes TM; Dellva MA; Waterman K; Greenbaum M; Poppe C; Goldberger C; Ahl J; Perahia DG
    Curr Med Res Opin; 2015 Jun; 31(6):1179-89. PubMed ID: 25894953
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 38.